Analysts Set Alto Neuroscience, Inc. (NYSE:ANRO) Target Price at $35.25

Posted by on Aug 8th, 2026

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $35.25.

Several equities research analysts recently commented on the stock. Zacks Research lowered shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. Bank of America started coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They set a “buy” rating and a $35.00 target price for the company. Wall Street Zen cut shares of Alto Neuroscience from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Robert W. Baird reduced their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Finally, Wolfe Research assumed coverage on shares of Alto Neuroscience in a research report on Friday, May 22nd. They issued an “outperform” rating on the stock.

Get Our Latest Stock Analysis on ANRO

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Quantinno Capital Management LP lifted its position in shares of Alto Neuroscience by 1.4% in the first quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock valued at $811,000 after acquiring an additional 490 shares in the last quarter. Torren Management LLC purchased a new stake in Alto Neuroscience during the 4th quarter worth about $62,000. XTX Topco Ltd increased its position in Alto Neuroscience by 32.2% during the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after purchasing an additional 5,078 shares in the last quarter. Renaissance Technologies LLC raised its stake in Alto Neuroscience by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock valued at $2,327,000 after purchasing an additional 6,100 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Alto Neuroscience by 26.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock valued at $884,000 after purchasing an additional 8,148 shares during the last quarter.

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $28.61 on Monday. The stock has a fifty day moving average price of $24.87 and a 200 day moving average price of $22.29. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. The stock has a market cap of $1.00 billion, a PE ratio of -11.82 and a beta of 1.06. Alto Neuroscience has a 1 year low of $3.02 and a 1 year high of $29.49.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.24). Sell-side analysts forecast that Alto Neuroscience will post -3.14 earnings per share for the current fiscal year.

Alto Neuroscience Company Profile

(Get Free Report)

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

Featured Stories

Analyst Recommendations for Alto Neuroscience (NYSE:ANRO)

Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.